Rannard SP - Search Results

1

Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation.

McDonald TO, Giardiello M, Martin P, Siccardi M, Liptrott NJ, Smith D, Roberts P, Curley P, Schipani A, Khoo SH, Long J, Foster AJ, Rannard SP, Owen A. McDonald TO, et al. Among authors: rannard sp. Adv Healthc Mater. 2014 Mar;3(3):400-11. doi: 10.1002/adhm.201300280. Epub 2013 Sep 1. Adv Healthc Mater. 2014. PMID: 23997027

2

Aligned two- and three-dimensional structures by directional freezing of polymers and nanoparticles.

Zhang H, Hussain I, Brust M, Butler MF, Rannard SP, Cooper AI. Zhang H, et al. Among authors: rannard sp. Nat Mater. 2005 Oct;4(10):787-93. doi: 10.1038/nmat1487. Epub 2005 Sep 25. Nat Mater. 2005. PMID: 16184171

3

Formation and enhanced biocidal activity of water-dispersable organic nanoparticles.

Zhang H, Wang D, Butler R, Campbell NL, Long J, Tan B, Duncalf DJ, Foster AJ, Hopkinson A, Taylor D, Angus D, Cooper AI, Rannard SP. Zhang H, et al. Among authors: rannard sp. Nat Nanotechnol. 2008 Aug;3(8):506-11. doi: 10.1038/nnano.2008.188. Epub 2008 Jul 6. Nat Nanotechnol. 2008. PMID: 18685640

4

One-pot, single-component synthesis of functional emulsion-templated hybrid inorganic-organic polymer capsules.

Harbron RL, McDonald TO, Rannard SP, Findlay PH, Weaver JV. Harbron RL, et al. Among authors: rannard sp. Chem Commun (Camb). 2012 Feb 1;48(10):1592-4. doi: 10.1039/c1cc15213k. Epub 2011 Oct 31. Chem Commun (Camb). 2012. PMID: 22042249

5

Nanomedicines for HIV therapy.

Siccardi M, Martin P, McDonald TO, Liptrott NJ, Giardiello M, Rannard S, Owen A. Siccardi M, et al. Ther Deliv. 2013 Feb;4(2):153-6. doi: 10.4155/tde.12.156. Ther Deliv. 2013. PMID: 23343155

6

Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients.

Martin P, Giardiello M, McDonald TO, Rannard SP, Owen A. Martin P, et al. Among authors: rannard sp. Mol Pharm. 2013 Jul 1;10(7):2739-48. doi: 10.1021/mp400175n. Epub 2013 Jun 10. Mol Pharm. 2013. PMID: 23701529

7

Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a 'mixed matrix'.

Liptrott NJ, Kendall E, Nieves DJ, Farrell J, Rannard S, Fernig DG, Owen A. Liptrott NJ, et al. Nanomedicine (Lond). 2014 Nov;9(16):2467-79. doi: 10.2217/nnm.14.38. Nanomedicine (Lond). 2014. PMID: 24938615

8

Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions.

Liptrott NJ, Giardiello M, Hunter JW, Tatham L, Tidbury LR, Siccardi M, Rannard S, Owen A. Liptrott NJ, et al. Nanomedicine (Lond). 2015 May;10(9):1407-21. doi: 10.2217/nnm.14.77. Epub 2014 Jul 23. Nanomedicine (Lond). 2015. PMID: 25055247

9

The application of nanotechnology in medicine: treatment and diagnostics.

Owen A, Dufès C, Moscatelli D, Mayes E, Lovell JF, Katti KV, Sokolov K, Mazza M, Fontaine O, Rannard S, Stone V. Owen A, et al. Nanomedicine (Lond). 2014 Jul;9(9):1291-4. doi: 10.2217/nnm.14.93. Nanomedicine (Lond). 2014. PMID: 25204820

10

Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz.

Siccardi M, Olagunju A, Seden K, Ebrahimjee F, Rannard S, Back D, Owen A. Siccardi M, et al. In Silico Pharmacol. 2013 Mar 1;1:4. doi: 10.1186/2193-9616-1-4. eCollection 2013. In Silico Pharmacol. 2013. PMID: 25505649 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

111 results

Search Page

Filters